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Molecular and cellular correlates of human
nerve regeneration: ADCYAP1/PACAP
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We only have a rudimentary understanding of the molecular and cellular determinants of nerve regeneration and neuropathic pain
in humans. This cohort study uses the most common entrapment neuropathy (carpal tunnel syndrome) as a human model system
to prospectively evaluate the cellular and molecular correlates of neural regeneration and its relationship with clinical recovery. In
60 patients undergoing carpal tunnel surgery [36 female, mean age 62.5 (standard deviation 12.2) years], we used quantitative sen-
sory testing and nerve conduction studies to evaluate the function of large and small fibres before and 6 months after surgery.
Clinical recovery was assessed with the global rating of change scale and Boston Carpal Tunnel Questionnaire. Twenty healthy
participants provided normative data [14 female, mean age 58.0 (standard deviation 12.9) years]. At 6 months post-surgery, we
noted significant recovery of median nerve neurophysiological parameters (P50.0001) and improvements in quantitative sensory
testing measures of both small and large nerve fibre function (P50.002). Serial biopsies revealed a partial recovery of intraepider-
mal nerve fibre density [fibres/mm epidermis pre: 4.20 (2.83), post: 5.35 (3.34), P = 0.001], whose extent correlated with symptom
improvement (r = 0.389, P = 0.001). In myelinated afferents, nodal length increased postoperatively [pre: 2.03 (0.82), post: 3.03
(1.23), P50.0001] suggesting that this is an adaptive phenomenon. Transcriptional profiling of the skin revealed 31 differentially
expressed genes following decompression, with ADCYAP1 (encoding pituitary adenylate cyclase activating peptide, PACAP) being
the most strongly upregulated (log2 fold-change 1.87, P = 0.0001) and its expression was associated with recovery of intraepider-
mal nerve fibres. We found that human induced pluripotent stem cell-derived sensory neurons expressed the receptor for PACAP
and that this peptide could significantly enhance axon outgrowth in a dose-dependent manner in vitro [neurite length PACAP
1065.0 mm (285.5), vehicle 570.9 lm (181.8), P = 0.003]. In conclusion, carpal tunnel release is associated with significant cutane-
ous reinnervation, which correlates with the degree of functional improvement and is associated with a transcriptional programme
relating to morphogenesis and inflammatory processes. The most highly dysregulated gene ADCYAP1 (encoding PACAP) was asso-
ciated with reinnervation and, given that this peptide signals through G-protein coupled receptors, this signalling pathway provides
an interesting therapeutic target for human sensory nerve regeneration.
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Introduction
Knowledge of cellular and molecular correlates of nerve re-
generation is critical to understand the temporal profile of
nerve regeneration as well as the determinants of successful
recovery.
Preclinical data suggest a complex interplay of several
pathways in regulating nerve regeneration including retro-
grade neuronal signalling (e.g. importin proteins), successful
Wallerian degeneration, phenotypic changes in Schwann
cells (e.g. growth factors, cell adhesion molecules such as
neuregulin 1), transcriptional changes in Schwann cells and
neurons (e.g. cAMP activated CREB, ATF-3, cJun,
microRNA) and local protein translation at the growth cone
(e.g. ZBP1 induced b-actin translation) (for review see
Scheib and Hoke, 2013).
While neural regeneration has been extensively studied in
animal models of peripheral nerve injury (Navarro, 2016;
Dubovy et al., 2018), studying the determinants of nerve re-
generation and its relationship to recovery in humans
remains challenging due to the limited access to tissues and a
lack of treatments to promote nerve regeneration. So far,
studies have mostly relied on sensory or motor reinnervation
times, the advancement of Tinel’s sign as well as the recov-
ery of action potentials in electrophysiological recordings
(Seddon et al., 1943; Dolenc and Janko, 1976; Buchthal and
Kuhl, 1979). Through these studies it has become evident
that human nerve regeneration is less successful compared to
regeneration identified in preclinical rodent experiments.
This may be attributed to the longer regeneration distances
and chronic denervation in humans, which is in contrast to
acute regeneration models over short distances commonly
studied in preclinical work (Hoke, 2006).
In the past decade, serial skin biopsies have provided
insights into the regeneration of small sensory axons in
humans (Rajan et al., 2003; Polydefkis et al., 2004; Hahn
et al., 2006; Petersen et al., 2010). Recently, skin biopsies
have also been used to obtain information about the integ-
rity of myelination and large nerve fibres (Nolano et al.,
2003; Schmid et al., 2014). However, a lack of knowledge
remains concerning the molecular and cellular determinants
of nerve regeneration and their relationship to clinical recov-
ery and specifically neuropathic pain in humans.
Here, we use carpal tunnel syndrome (CTS) as a model
system to study sensory nerve regeneration in humans after
chronic denervation. CTS is one of the few neuropathic con-
ditions that can be treated surgically. It therefore provides a
unique model system to prospectively study the cellular and
molecular correlates of nerve regeneration and their relation-
ship to clinical recovery in humans. We deeply phenotyped
patients before and 6 months after carpal tunnel decompres-
sion including electrophysiology, quantitative sensory test-
ing, symptom profiling and functional deficits. Using serial
skin biopsies, we determined the postoperative reinnervation
of sensory target tissue with histology as well as the molecu-
lar signature associated with regeneration using RNA
sequencing. This revealed that ADCYAP1 was the most dif-
ferentially expressed gene (DEG). ADCYAP1 encodes
PACAP (pituitary adenylate cyclase-activating peptide),
which has pleiotropic functions, including as a neurotrophic
factor, neuromodulator and neurotransmitter (Waschek,
2002; Tamas et al., 2012). PACAP binds with high affinity
to three receptors (PAC1, VPAC1 and VPAC2). Whereas
PAC1 specifically binds PACAP, the VPAC receptors have
equal affinity for PACAP and VIP (vasointestinal peptide).
We found ADCYAP1 and its receptors expressed in human
induced pluripotent stem cell-derived (hiPSCd) sensory neu-
rons in vitro as well as in human skin, with PACAP and
PAC1 specifically expressed in human sensory afferents.
There is a body of predominantly preclinical evidence impli-
cating ADCYAP1/PACAP with neural regeneration (for re-
view see Waschek, 2002) through downstream cAMP
signalling (Guirland et al., 2003; Ravni et al., 2008; Emery
and Eiden, 2012). We therefore studied the effect of PACAP
given to hiPSCd-sensory neurons and found it enhanced neu-
rite outgrowth in a dose-dependent way. A similar regenera-
tive effect of the selective PAC1 agonist (maxadilan) suggests
that manipulation of PACAP/PAC1 may have therapeutic
potential in human sensory nerve regeneration.
Materials and methods
Study design and participants
This study used a prospective longitudinal cohort design. Seventy-
three patients with clinically and electrodiagnostically confirmed
CTS were recruited from the surgical waiting lists at Oxford
University Hospitals NHS Foundation Trust. Patients were
excluded if electrodiagnostic testing revealed abnormalities other
than CTS, if another medical condition affecting the upper limb
and neck was present (e.g. hand osteoarthritis, cervical radiculop-
athy), if there was a history of significant trauma to the upper
limb or neck, or if CTS was related to pregnancy or diabetes.
Patients undergoing repeat carpal tunnel surgery were excluded.
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Whereas 60 patients underwent surgery and were included in the
main cohort, 13 patients opted out of surgery after being con-
sented, with the study team having no role in these patients’ deci-
sions. While these patients were not the main focus of the study,
we continued to follow them over time and report their data as a
separate cohort. A cohort of 20 healthy volunteers (proportionally
age- and gender-matched to the CTS surgery group) without any
systemic medical condition, or a history of hand, arm or neck
symptoms, served as healthy control subjects.
The study was approved by the London Riverside national re-
search ethics committee (Ref 10/H0706/35), and all participants
gave informed written consent in accordance with the Declaration
of Helsinki. Whereas the healthy participants only attended a sin-
gle session, all patients attended two appointments, one at base-
line and a follow-up appointment (6 months after surgery/
baseline appointment). In patients with CTS, the hand that was
operated (surgery group) or the hand that was more affected (no-
surgery group) was tested, whereas the non-dominant hand was
tested in healthy controls. All clinical measurements were col-
lected by the same experienced examiner to ensure consistency.
Sample size calculation
The required sample size was a priori determined with G-Power
software (Faul et al., 2007) for the primary outcome measure of
small fibre regeneration following surgery using previous data
from the cross-sectional Oxford CTS cohort (Schmid et al.,
2014). Fifty-nine patients were required to detect a 20% in-
crease in intraepidermal nerve fibre density (IENFD) with 80%
power, significance set at a = 0.05 and an effect size of 0.328.
Clinical phenotype
Symptom and function questionnaires
Patients with CTS completed the Boston Carpal Tunnel
Questionnaire (symptom and function scale; 0 = no symptoms/
disability, 5 = very severe symptoms/disability) (Levine et al.,
1993) to determine symptom severity and functional deficits.
Clinical recovery was determined with two global rating of
change scales (GROC) (Jaeschke et al., 1989) evaluating
changes in hand symptoms and function. The GROC scales
range from ‘a very great deal better’ ( + 7), to ‘a very great deal
worse’ (–7) with a change of 55 (a good deal better/worse)
considered clinically meaningful (Kamper, 2009). In addition,
we calculated the difference in the Boston questionnaire sub-
scales (follow-up minus baseline).
Electrodiagnostic tests
Electrodiagnostic tests were performed with an ADVANCETM
system (NeuroMetrix) for sensory and motor latencies and
amplitudes of the median, ulnar and radial nerve as previously
described (Schmid et al., 2014) (Supplementary material).
Electrodiagnostic testing was graded according to the scale by
Bland (2000) ranging from very mild (1), to extremely severe
(6). During data analysis, absent sensory and motor recordings
were replaced with values of zero for amplitudes but excluded
from analysis of latencies and nerve conduction velocities to pre-
vent inflated results.
Quantitative sensory testing
Quantitative sensory testing (QST) was carried out according to
the standardized protocol published by the German research
network of neuropathic pain (Rolke et al., 2006). Cold and
warm detection (CDT, WDT) and cold and heat pain thresholds
(CPT, HPT) as well as thermal sensory limen (TSL) were meas-
ured with a thermotester (Somedic). We also examined mechan-
ical detection (MDT), vibration detection (VDT), mechanical
pain thresholds (MPT), pressure pain thresholds (PPT), wind up
ratio (WUR) and mechanical pain sensitivity (MPS). The num-
ber of paradoxical heat sensations during TSL and the presence
of dynamic mechanical allodynia were quantified. All measure-
ments apart from PPT and VDT were performed over the pal-
mar aspect of the proximal phalanx of the index finger. PPT
was recorded over the thenar eminence and VDT over the pal-
mar side of the distal end of the second metacarpal. To achieve
normally distributed data, all QST parameters, expect for CPT,
HPT and VDT, were log-transformed (Magerl et al., 2010).
A small constant of 0.1 was added to MPS to avoid loss of
zero-rating values. Most QST measures have good to excellent
long-term reliability except for WUR, which has fair retest reli-
ability over a period of 4 months (Marcuzzi et al., 2017;
Nothnagel et al., 2017).
Histological analysis of target tissue
Skin biopsies
Two serial skin biopsies (3 mm diameter) were taken 6 months
apart on the ventrolateral aspect of the proximal phalanx of the
index finger, innervated by the median nerve. The second biopsy
was taken a few millimetres more proximal, avoiding the primary
biopsy site. One surgical patient received warfarin and no follow-
up biopsy was thus taken. The biopsies were performed under
sterile conditions following local anaesthesia with 1% lidocaine
(1–1.8 ml). Whereas half of the biopsy was snap-frozen for tran-
scriptional analysis (see below), the other half was fixed in fresh
periodate-lysine-paraformaldehyde for 30 min before being
washed in 0.1 M phosphate buffer and cryoprotected in 15% su-
crose in 0.1 M phosphate buffer. The tissue was embedded in
OCT, frozen and stored at –80. To ensure consistency, each
histological analysis was carried out by the same blinded observer.
Intraepidermal nerve fibre density
Sections (50 lm) were cut on a cryostat and stained using a pre-
viously described protocol (Schmid et al., 2014). Serial biopsies
of the same patient were processed simultaneously to minimize
variability. Sections were blocked with 5% fish gelatine before
incubation with the primary antibodies for myelin basic protein
(MBP, Abcam, 1:500) and protein gene product 9.5 (PGP,
Ultraclone, 1:1000) overnight. Secondary antibodies were also
incubated overnight (Alexa 488 1:1000, Abcam; Cy3, Stratech
1:500). The PGP antibody from Ultraclone was discontinued
during our study and replaced with the PGP antibody from
Zytomed (1:200) after successful benchmarking.
IENFD was established by counting three sections per partici-
pant using an Axio LSM 700 microscope (Zeiss) (Lauria et al.,
2010). Sections were then photographed at 20 magnification
(Observer Z1, Zeiss) and epidermal length was measured with
ImageJ (NIH, USA). Average IENFD was expressed as fibres/
mm epidermis. Intra-rater reliability to determine IENFD was
examined by processing and counting n = 23 skin samples twice,
1 week apart. Intraclass correlation coefficient (ICC) revealed al-
most perfect intra-rater agreement for IENFD [ICC(2,1) 0.913
(95% confidence interval 0.791–0.963), P50.0001].
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Myelinated fibre integrity
We used several approaches to evaluate myelinated fibre integ-
rity. First, we quantified the number of Meissner corpuscles per
mm epidermis as previously reported (Schmid et al., 2014).
Second, dermal nerve bundles containing myelinated fibres were
expressed as a ratio of total PGP9.5 + nerve bundles containing
at least five PGP + axons per mm2 dermis (excluding the subepi-
dermal plexus). Third, we measured the length of nodes of
Ranvier in the subepidermal plexus of MBP/PGP double-stained
sections in up to 10 sections/participant. This was achieved with
the Zen black software (Zeiss) on confocal image stacks taken
at 40 magnification as previously reported (Schmid et al.,
2014). Nodes were classified as elongated if they exceeded 6.1
lm in length (Doppler et al., 2013). If fewer than 15 nodes
were identified, patients were excluded from the analysis (n = 8).
Subepidermal plexus length
We used unbiased stereology to estimate nerve fibre length in
the subepidermal plexus using a previously described method-
ology (Karlsson et al., 2013). Estimation of nerve fibre length in
the subepidermal plexus was performed on PGP stained skin sec-
tions using an Olympus BX51 microscope (60 oil immersion
lens) and newCAST stereological software (Visiopharm) in a
blinded fashion. A virtual plane probe was used, as it generates
isotropy of the test planes and allows length estimation of tubu-
lar objects in thick sections with arbitrary directions. The region
of interest was the subepidermal plexus, here defined as an area
deep to the epidermal-dermal junction and 200 lm towards the
dermis. Papillae were excluded as they contain Meissner cor-
puscles, which are not part of the subepidermal plexus and their
irregular distribution may have biased the results. Briefly, 3D
sampling boxes are superimposed over the skin section, thereby
generating randomized isotropic virtual planes in systematically
sampled fields of view (Karlsson et al., 2013). Sampling box
height was set to 15 lm and the box area size to 7908 lm2.
Sampling steps were 85  70 lm (in the x and y-direction), with
a plane separation distance of 25 lm. Four sections were typical-
ly counted per patient (ranging from three to six) and nerve fibre
length expressed as length per squared area.
Statistical analysis of clinical and
histological data
Data were analysed using SPSS (version 24, IBM) and R soft-
ware (Team, 2018). Normal distribution of clinical and histo-
logical data was established by visual inspection and with the
Kolmogorov-Smirnov test for normality.
The main statistical comparison concerned the pre- versus
post-surgical data. This was achieved using two-sided paired t-
tests or Wilcoxon signed rank tests for parametric and non-
parametric data, respectively. In order to establish differences at
baseline and the extent of recovery, pre- and post-surgical data
of patients with CTS were compared with healthy control data
using two-sided independent t-tests or Mann Whitney U-tests
where appropriate. To control for false discovery rate (FDR),
Benjamini-Hochberg correction was applied for three compari-
sons with the false discovery rate set to 5% (Benjamini and
Hochberg, 1994). Unadjusted P-values are reported for ease of
interpretation. Data of non-operated patients were analysed and
reported using the same statistical analyses as for operated
patients.
Correlation of histological findings with changes in
symptomatology/function
Spearman’s correlation analyses were performed in the full pa-
tient cohort to determine associations between the extent of clin-
ical recovery and neural regeneration. The extent of neural
regeneration was determined by calculating the difference (fol-
low-up minus baseline) of the histological parameters, which
changed significantly after surgery (IENFD, percentage of elon-
gated nodes, mean nodal length). Clinical recovery was eval-
uated with the global rating of change questionnaire (for
symptoms and function) as well as with the difference in Boston
questionnaire (follow-up minus baseline for symptoms and func-
tion subscales). Benjamini-Hochberg correction was used to cor-
rect for multiple testing (12 correlations), with unadjusted P-
values reported. To aid interpretation, Boston questionnaire
data were multiplied by –1 so that a positive correlation always
corresponds with more pronounced clinical recovery.
Molecular analysis of target tissue
RNA sequencing
Half of the skin biopsies of 47 patients with CTS (n = 29
females) before and after surgery were snap-frozen in liquid ni-
trogen. RNA was extracted using a combination of phenol ex-
traction and column purification. Samples were homogenized in
TRIzolTM and mixed with chloroform before spinning for phase
separation. The aqueous liquid phase containing the nucleic
acids was removed and added to the columns of the High Pure
RNA tissue kit (Roche Diagnostics). RNA was purified using
repeated wash steps and DNAse treatment. The extracted RNA
was sent for sequencing at the Wellcome Trust Centre for
Human Genetics in Oxford, UK. All samples were normalized
to 650 ng prior to library preparation using the TruSeq
Stranded Total RNA Library Prep Kit (Illumina) and poly-A en-
richment. Paired-end sequencing was performed using the
HiSeq4000 platform with a read length of 75 bp.
Reads were mapped to the GRC.h.38 Human genome using
STAR, gene counts were generated using HTSeq and DEG ana-
lysis was performed using DESeq2 as outlined in detail in the
Supplementary material. Gene ontology enrichment for biologic-
al processes for DEGs was carried out using topGO (Alexa and
Rahnenfuhrer, 2018) and GSEA (Morgan et al., 2017).
Gene to regenerative phenotype association
Fold gene expression changes relative to baseline [(post-surgery
– pre-surgery) / pre-surgery] and individual baseline expression
of significant DEGs were tested for association with fold
changes and post- versus pre- differences in IENFD and nodal
length. This was achieved by testing significant Pearson correl-
ation coefficients and by binning the continuous outcomes into
four categories corresponding to the four quarters, as defined by
the outcome quartiles with significance assessed using one-way
ANOVA. In all associations of gene expression or fold change
to phenotype, significance cut-off was an FDR-adjusted P-value
5 0.05.
Droplet digital PCR to validate RNA sequencing
The findings of the RNA sequencing were validated in 78 paired
samples pre- and post-surgery (n = 39 patients) using droplet
digital PCR (ddPCR). Complementary DNA was prepared using
the EvoScript Universal cDNA Master kit (Roche Diagnostics).
TaqManTM assays (Thermo-Fisher) for ADCYAP1
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(Hs00174950_m1) and HPRT1 (Hs03929098_m1) were run in
duplicates with 1 ll of target probe labelled with FAM added to
1 ll of reference probe labelled with VIC in the same reaction
using the ddPCR Supermix for Probes (Bio-Rad). QuantaSoft
v1.7.4.0917 software (Bio-Rad Laboratories) was used to ex-
tract data (copies/ll) and normalized gene expression was
reported (ratios of target over reference data).
Localization of PACAP and PAC1 in skin biopsies
The localization of PACAP (encoded by ADCYAP1) expression
in skin biopsies was evaluated using an immunofluorescent
staining protocol adapted from Hannibal et al. (1995). In brief,
50-lm skin sections were mounted on glass slides and incubated
in 10% goat serum in phosphate-buffered saline (PBS) and
TritonTM X-100 for 30 min. Primary antibodies for PACAP
(gift from Prof Jan Fahrenkrug, 1:5) and PGP9.5 (Zytomed,
1:200) were incubated overnight.
A biotinylated goat anti-mouse antibody (Vector Laboratories,
1:200) was then applied for 2 h along with an Alexa FluorV
R
546
anti-rabbit antibody (Life Technologies, 1:500). After five
washes, the sections were incubated for 30 min with an avidin-
biotin-horseradish peroxidase (VECTASTAINV
R
Elite ABC Kit,
Vector Laboratories) before washing four times. The sections
were incubated for 10 min in FITC conjugated tyramide (Perkin
Elmer, 1:100) diluted in 0.1 M borate buffer containing
0.0003% hydrogen perioxide. After three washes, slides were
coverslipped in mounting medium and imaged on an Observer
Z1 confocal imaging system (Zeiss) using the same settings with-
in each patient (pre and post-surgery). Whereas the specificity of
the PACAP antibody has been extensively evaluated (Hannibal
et al., 1995), we included a negative control (omission of pri-
mary antibody) as well as a pre-adsorption control. We quanti-
fied average PACAP staining intensity of n = 10 patients before
and after surgery using ImageJ (NIH USA) within (i) an area
overlying the epidermis and subepidermal plexus including both
neuronal and non-neuronal structures; and (ii) specifically within
PGP + nerve fibres using thresholding.
Further, potential PAC1 localization in human skin afferents
was determined by double immunostaining with PAC1
(Cambridge Bioscience, 1:100) and PGP (Bio-Rad, 1:200). In
brief, 50 lm skin sections were heat treated for 5 min in 10
mM citric acid with 0.05% Tween 20 followed by 30 min incu-
bation in 10% goat serum in PBS and TritonTM X-100 and pri-
mary antibody incubation overnight. The next day, sections
were washed and incubated with biotinylated goat anti-rabbit
antibody (Vector Laboratories, 1:200) for 2 h followed by
Alexa FluorV
R
546 anti-mouse antibody (Life Technologies,
1:1000) and Streptavidin (Life Technologies, 1:500) for 2 h.
Sections were then mounted and imaged on an Observer Z1
confocal imaging system (Zeiss).
In vitro expression and role of
ADCYAP1/PACAP
RNA-sequencing of human induced pluripotent
stem cell-derived sensory neurons
We interrogated our data from a previous RNA sequencing ex-
periment (Baskozos et al., 2019) in hiPSCd sensory neurons,
which replicate many of the molecular, morphological and func-
tional features of native human sensory neurons (Chambers
et al., 2012; Clark et al., 2017; McDermott et al., 2019). The
hiPSCd sensory neurons were generated as previously described
(Clark et al., 2017). RNA was extracted with the hybrid method
of combined phenol extraction (TriPure, Roche) and column
purification (High Pure RNA tissue Kit, Roche). Sequencing
was performed using the Illumina HiSeq4000 paired-end proto-
col with 75-bp reads. Reads were mapped on the Hg38
(GRCh38) human genome using STAR with the default
ENCODE options. Gene counts were calculated for the
GRCh38.88 gene set annotation using HTSeq. Data are avail-
able in the GEO series GSE107181. We evaluated ADCYAP1
and its primary receptor PAC1 as well as secondary receptors
VPAC1 and VPAC2 with affinity for PACAP and VIP (vaso-
active intestinal protein) expression levels compared to other
genes.
Differentiation of human induced pluripotent stem
cell-derived sensory neurons
We used two control iPSC lines derived from fibroblasts of a
healthy 44-year-old female (Subject NHDF) (Hartfield et al.,
2014) and a healthy 51-year-old male (Subject AD2) (NRES
Committee South Central – Berkshire, UK, REC 10/H0505/71).
The lines were differentiated to sensory neurons as previously
described (Chambers et al., 2012; Clark et al., 2017; Weir et al.,
2017) and as outlined in the Supplementary material.
Human sensory neuron regeneration model
To determine a potential regenerative role of PACAP in human
primary sensory neurons, we dissociated mature hiPSCd sensory
neurons and assessed their ability to regenerate neurites, as we
have previously described (McDermott et al., 2019). Neurons
were enzymatically treated for 30 min with 0.1% Trypsin
(ThermoFisher), followed by mechanical dissociation with a fire
polished glass pipette. Single cells were replated onto
MatrigelTM treated coverslips at low density in the presence of
different doses of PACAP protein (10 nM to 10 lM, AnaSpec
and Bachem), vehicle (0.01% DMSO, Sigma) or the selective
PAC1 agonist maxadilan (1 lM, Bachem) before fixation and
analysis by immunocytochemistry 18 h later.
Quantification of neurite outgrowth
Three differentiations of mature hiPSCd sensory neurons were
used (27±3 weeks old). Neurons were taken from individual
wells of a 24-well plate and dissociated separately to form each
experimental unit (n). Four dissociation experiments were per-
formed. Average neurite outgrowth was calculated from 6–10
technical replicates (individual coverslips of re-plated neurons)
per n (for n in each experiment, refer to single datapoints in
graphs). The vehicle- and PACAP-treated hiPSCd sensory neu-
rons were immunostained with NF200 using immunohistochem-
istry. NF200 has been shown to be expressed in virtually all
DRG neurons in humans (Chang et al., 2018). The NF200 anti-
body (Sigma, 1:500) was added to hiPSCd sensory neurons
overnight at room temperature. Neurons were then washed
three times with PBS + TritonTM X-100 and a secondary anti-
mouse antibody Alexa FluorV
R
488 (Life Technologies: 1:1000)
was added for 2 h at room temperature. The neurons were
washed three times with PBS + TritonTM X-100 and the cover-
slips were mounted with VECTASHIELDV
R
on slides and sealed.
To determine neurite outgrowth, 20 magnified images of in-
dividual hiPSCd sensory neurons were taken on an Observer Z1
imaging system (Zeiss) and analysed for neurite length using
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WIS-Neuromath software (Rishal et al., 2013). Only neurons
with a neurite at least half the diameter of the cell body were
included. Neurite length was determined in micrometre per cell
and the resultant neurite length from individual neurons was
averaged per coverslip [median number of neurons/dissociation
49 (interquartile range, IQR 73)]. Independent t-tests or one-
way ANOVA followed by Fisher’s least significant difference
(LSD) post hoc tests were used to compare neurite length among
conditions.
Neuronal binding of PACAP (biotinylated protein, AnaSpec)
and localization of PAC1 (Cambridge Bioscience, 1:50) in
hiPSCd sensory neurons was examined by double-labelling with
NF200 (Abcam, 1:2000) using the immunohistochemistry
protocol outlined above.
Data availability
The data that support the findings of this study are deposited in
the dbGaP repository (https://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?study_id=phs001796.v1.p1).
Results
The majority of patients show
significant symptomatic and
functional improvement
Sixty patients with electrodiagnostically confirmed CTS
[mean age 62.5 (standard deviation, SD 12.2), 36 females]
were examined before and 6 months after decompression sur-
gery. Twenty healthy volunteers served as healthy controls
[mean age 58.0 (12.9), 14 females] (Table 1). Post-surgically,
83.3% of patients rated their symptoms at least ‘a good deal
better’ (55) on the global rating of change scale. None of the
patients experienced a deterioration of symptoms. In relation
to hand function, 63.3% of operated patients felt at least ‘a
good deal better’. The self-perceived symptoms and function
improvements were consistent with a postoperative decrease
of the Boston Carpal Tunnel Questionnaire symptom and
function subscales [Boston symptoms mean (SD) pre: 2.8
(0.7), post: 1.5 (0.5), t(59) = 13.8, P5 0.0001; Boston
function pre: 2.2 (0.8), post: 1.5 (0.5), t(59) = 7.00,
P5 0.0001]. However, symptoms did not fully resolve in all
patients, and 46.6% continued to have some pain and 38.3%
to feel paraesthesia or numbness, although these residual
symptoms were mostly mild in nature.
Electrodiagnostic test severity
improves following surgery, but fails
to reach normal levels in most
patients
Electrodiagnostic testing demonstrated moderate severity
preoperatively [median Bland scale 3.0 (IQR 2.8)]. After sur-
gery, electrodiagnostic test severity improved by one grade
to an average of mild severity [2.0 (2.0), z(55) = –5.62,
P5 0.0001] (Table 2). With the exception of eight patients
(4.8%), in whom electrodiagnostic testing was within nor-
mal limits following surgery, all patients continued to show
some degree of median nerve conduction slowing.
Sensory detection thresholds
improve following surgery, but fail
to reach normal levels
Somatosensory function and its recovery measured with
quantitative sensory testing in the median innervated territory
of the hand can be found in Table 3 and Fig. 1A–C. Patients
with CTS had a significant pre-surgical deficit in all thermal
and mechanical detection thresholds compared to healthy
control subjects [t(78) 4 2.30, P50.015]. Cold detection,
thermal sensory limen, mechanical and vibration detection
improved following surgery [t(59) 4 3.20, P50.002]. Only
warm detection thresholds remained unchanged post-surgery
[t(59) = 1.58, P = 0.120]. Postoperative detection thresholds,
however, mostly failed to reach levels found in healthy con-
trol participants [t(75) 4 2.00, P5 0.033].
Thermal and mechanical pain thresholds were not differ-
ent between healthy controls and preoperative CTS patients
(P4 0.402, Fig. 1D–F) and remained largely unaltered
Table 1 Demographic and clinical data of patients with carpal tunnel syndrome and healthy volunteers
Surgery No-surgery Controls P-value
Number of participants 60 13 20
Gender, female/male (% female) 36/24 (60.0) 9/4 (69.2) 14/6 (70.0) 0.649#
Mean age, years (SD) 62.5 (12.2) 53.6 (11.9)* 58.0 (12.9) 0.044
Mean weight, kg (SD) 74.4 (15.0) 74.1 (13.1) 73.6 (15.7) 0.978
Mean height, cm (SD) 168.4 (9.5) 165.2 (8.8) 167.0 (7.6) 0.472
Mean symptom duration, months (SD) 64.2 (96.5) 52.7 (44.8) 0.676
Mean Boston scale (SD)
Symptoms 2.8 (0.7) 2.3 (0.6)* 0.008
Function 2.2 (0.8) 1.9 (0.6) 0.184
Comparisons were done with one-way ANOVA and independent t-tests.
#Comparisons were done with chi-squared test.
*Statistical significance compared to surgery group.
NPSI = neuropathic pain symptom inventory; SD = standard deviation.
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following surgery (P4 0.221). The only exception was an
increased sensitivity to cold pain following surgery com-
pared to before surgery [t(59) = –2.04, P = 0.046]. Of four
patients with preoperative paradoxical heat sensations, one
patient continued to paradoxically feel heat on cooling post-
operatively and two patients experienced new paradoxical
heat sensations postoperatively. No patient presented with
dynamic mechanical allodynia pre- or postoperatively.
Intraepidermal nerve fibres partially
regenerate following surgery
We next evaluated structural integrity of sensory target tis-
sue innervation. Skin biopsies in the median nerve inner-
vated territory of the hand showed a substantial structural
degeneration of small axons in the epidermal layer of
patients’ skin compared to healthy controls [fibres/mm epi-
dermis in CTS preoperative mean (SD): 4.20 (2.83); healthy
controls: 8.03 (2.08), t(77) = 5.3, P50.0001] (Fig. 2A–C).
Following surgery, IENFD improved [5.35 (3.34), t(57) =
–3.5, P = 0.001], but failed to reach normal innervation
levels [t(77) = 3.4, P = 0.001]. Of note, postoperative
regeneration was highly variable (Fig. 2D).
Subepidermal plexus nerve fibre
length density remains unchanged
Given the incomplete epidermal reinnervation following sur-
gery, we hypothesized that regenerating axons may reach
the dermis but their penetration through the dermal-epider-
mal junction may be delayed (Navarro et al., 1997; Rajan
et al., 2003). However, evaluation of nerve fibre length dens-
ity in the subepidermal plexus did not reveal any differences
in patients pre- and post-surgery [median mm–2 (IQR) pre:
70.25 (48.98); post: 75.85 (63.95), z(57) = 1.07, P = 0.285]
(Supplementary Fig. 1A).
Nodal architecture changes
following surgery
To evaluate changes in myelinated fibres, we examined nodal
architecture, which was previously found altered in patients
with CTS (Schmid et al., 2014) (Fig. 2F–J). At baseline, the
median nodal length [healthy: 2.54 IQR (0.98); CTS: 2.03
(0.82), z(77) = –1.70, P = 0.088] (Fig. 2H) and the percentage
of elongated nodes 4 6.1 lm [healthy: 0.00 (7.92); CTS:
0.00 (4.76), z(66) = –0.30, P = 0.767] (Fig. 2I) were
Table 2 Median nerve neurophysiology data of patients with CTS pre- and post-surgery
Surgery group Healthy controls
Pre Post P-value Baseline P-value (HC-pre) P-value (HC-post)
SNAP, lV 2.8 [8.2] 6.0 [5.5] 0.004 13.5 [11.1] 50.0001 50.0001
Sensory NCV, m/s 34.5 [7.9] 41.5 [6.15] 50.0001 50.2 [6.9] 50.0001 50.0001
Distal motor latency, ms 5.4 [1.8] 4.3 [1.0] 50.0001 3.1 [0.7] 50.0001 50.0001
CMAP, mV 4.1 [4.1] 5.2 [4.7] 0.299 7.7 [2.9] 0.001 0.005
Delay ulnar-median 1.6 [1.5] 0.8 [0.4] 50.0001 0.2 [0.2] 50.0001 50.0001
Data are presented as median [IQR]. CMAP = compound motor action potential; delay ulnar-median = delay between the motor potentials for dorsal interossei (ulnar nerve) and
lumbricals (median nerve) measured over an 8 cm wrist segment; HC = healthy controls; NCV = nerve conduction velocity; SNAP = sensory nerve action potential.
P-values that were significant following Benjamini-Hochberg correction are highlighted in bold.
Table 3 Quantitative sensory testing data of patients pre- and 6 months post-surgery as well as healthy controls
Surgery group Healthy controls
Pre Post P-value (pre post) Baseline P-value (HC-pre) P-value (HC-post)
CDT, C –5.66 (4.95) –3.38 (2.33) 50.0001 –2.28 (0.97) 50.0001 0.033
WDT, C 5.25 (3.89) 4.40 (3.24) 0.120 3.01 (1.66) 50.0001 0.022
TSL, C 11.15 (8.38) 8.74 (5.73) 0.002 5.53 (2.89) 0.002 0.023
MDT, mN 8.45 (19.00) 3.01 (8.90) 50.0001 0.38 (0.26) 50.0001 0.006
VDT, x/8 7.45 (0.74) 7.78 (0.54) 50.0001 7.88 (0.32) 0.015 0.429
CPT, C 9.42 (7.00) 11.44 (7.01) 0.046 7.88 (0.25) 0.484 0.698
HPT, C 44.06 (3.94) 43.74 (3.45) 0.481 10.72 (7.56) 0.484 0.664
MPT, mN 180.4 (125.7) 157.2 (103.3) 0.264 153.44 (85.33) 0.657 0.357
MPS, 0–100 0.59 (1.11) 0.41 (0.39) 0.569 0.56 (1.00) 0.782 0.386
PPT, kPa 180.4 (125.7) 157.3 (103.3) 0.221 351.36 (86.22) 0.747 0.452
WUR, ratio 2.53 (2.70) 2.53 (2.24) 0.810 2.04 (1.21) 0.402 0.302
Data are presented as mean (SD) for untransformed data (CPT, HPT, VDT) and retransformed mean for log-tranformed data. P-values reflect statistics carried out on log-trans-
formed data as appropriate comparing pre- and postoperative data (pre post), healthy controls with CTS patients pre-surgery (HC-pre) and healthy controls with CTS patients
post-surgery (HC-post). P-values that were significant following Benjamini-Hochberg correction are highlighted in bold. CDT = cold detection threshold; CPT = cold pain thresh-
old; HPT = heat pain threshold; MDT = mechanical detection threshold; MPS = mechanical pain sensitivity; MPT = mechanical pain threshold; PPT = pressure pain threshold;
TSL = thermal sensory limen; VDT = vibration detection threshold; WDT = warm detection threshold; WUR = wind-up ratio.
Correlates of human nerve regeneration BRAIN 2020: 143; 2009–2026 | 2015
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article/143/7/2009/5870171 by U
niversity of G
lasgow
 user on 11 January 2021
comparable in patients with CTS and healthy controls.
Following surgery, median nodal length [3.03 (1.23),
z(56) = 4.36, P5 0.0001] and the percentage of elongated
nodes increased in patients [post: 6.66 (15.79), z(46) = 4.10,
P50.0001] and remained higher than healthy controls
[z(77) = 2.58, P = 0.010 and z(66) = 2.85, P = 0.004, re-
spectively] (Fig. 2F–I).
The density of Meissner corpuscles, the number of PGP +
axon bundles per mm2 dermis and the ratio of dermal
PGP + axon bundles containing myelin remained unchanged
at baseline and after surgery (Supplementary Fig. 1B–D).
Deterioration in small fibre integrity
in patients not undergoing surgery
A small number of patients (n = 13) opted not to undergo
surgery. These were slightly younger and had less severe
symptoms at baseline compared to those undergoing surgery
(Table 1). Of note, non-operated patients demonstrated a
continuing degeneration of their IENFD over time [mean
baseline: 6.94 (SD 3.09); follow-up: 5.61 (3.41), t(12) =
2.66, P = 0.021] (Fig. 2D). Data for the other clinical and
histological measures of non-operated patients are summar-
ized in Table 4.
Neural regeneration correlates with
symptom improvement
The extent of small fibre regeneration positively correlated
with symptom improvement as determined with the Boston
symptom questionnaire [r(70) = 0.389, P = 0.001] (Fig. 2E).
A postoperative increase in nodal length [r(67) = 0.302,
P = 0.012] (Fig. 2J) and percentage of elongated nodes with
GROC for hand function marginally failed to reach signifi-
cance after Benjamini Hochberg correction [r(56) = 0.306,
P = 0.019]. None of the other correlations were significant
(P4 0.144).
Thirty-one genes, including
ADCYAP1, are differentially
expressed following surgery
To determine a molecular signature associated with nerve re-
generation, we performed RNA sequencing of the skin of 47
patients with CTS (n = 29 females) before and after surgical
decompression. RNA sequencing revealed 31 significant
DEGs in CTS patients post- versus pre-surgery (Fig. 3A and
B, Supplementary Fig. 2 and Supplementary Table 1). Gene
ontology enrichment analysis for biological processes high-
lighted biological processes relating to morphogenesis (such
as proximal/distal pattern formation, angiogenesis, embryon-
ic limb morphogenesis) and inflammation (such as interleu-
kin 1-beta production and cytokine biosynthetic process)
(Fig. 3C and Supplementary Table 2). The most significantly
dysregulated gene was ADCYAP1 (log2 fold change = 1.87,
FDR P-value = 0.0001) (Fig. 3A and B). ADCYAP1 encodes
PACAP, which is a highly evolutionary conserved protein
that is involved in a range of physiological processes includ-
ing neuronal survival after injury and neurite outgrowth
Figure 1 Recovery of somatosensory function. Raw quantitative sensory testing data are presented as mean and standard deviations for
healthy participants (n = 20, black circles) and patients with CTS before (closed red circle) and after surgery (n = 60, open red circle). (A) Cold
(CDT) and warm detection thresholds (WDT); (B) thermal sensory limen (TSL); (C) mechanical (MDT) and vibration detection thresholds
(VDT); (D) cold (CPT) and heat pain thresholds (HPT); (E) mechanical (MPT) and pressure pain thresholds (PPT); (F) mechanical pain sensitivity
(MPS) and wind-up ratio (WUR). Significant differences for paired/independent t-tests after Benjamini Hochberg correction are indicated be-
tween groups with #P5 0.05, ##P5 0.01, ###P5 0.0001 and within groups with *P5 0.05, **P5 0.01, ***P5 0.0001.
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Figure 2 Histological evidence nerve regeneration in target tissue. Immunohistochemically stained sections of index finger skin of a pa-
tient with CTS before (A) and 6 months after surgery (B). Cell nuclei are apparent in blue (DAPI) and axons in red (PGP9.5). After surgery, an
increased number of small fibres (arrows on 4 magnified regions of interest on the right) penetrate the dermal-epidermal border (dotted line).
(C) Quantification revealed a reduced IENFD in patients with CTS compared to healthy controls, which increased after surgery but failed to
reach normal levels. (D) The difference in IENFD post- compared to pre-surgery demonstrated a high interindividual variability, with a continuing
small fibre degeneration in patients who were not operated on. (E) A more pronounced intraepidermal nerve fibre regeneration (difference
IENFD) correlates with improved symptoms (r = 0.389, P = 0.001, difference Boston symptom scale data multiplied with –1). (F–J) Changes in
nodal architecture. Example of normal (F) and elongated node (G) in skin sections stained immunohistochemically with PGP9.5 and myelin basic
protein (MBP). (H) Median nodal length and (I) the median percentage of elongated nodes 46.1 lm increase following surgery and remain higher
than healthy controls. (J) The correlation between difference in mean nodal length and the global rating of change scale (GROC) for hand func-
tion marginally fails to reach significance after Benjamini Hochberg correction (r = 0.316, P = 0.008). Significant differences for paired/independent
t-tests after Benjamini Hochberg correction are indicated between groups with #P5 0.05, ##P5 0.01, ###P5 0.0001 and within groups with
**P5 0.01, ***P5 0.0001. Group differences based on n = 59 patients with CTS and n = 20 healthy control subjects.
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(Waschek, 2002). We confirmed the increased expression of
ADCYAP1 in skin samples following surgical release using
ddPCR (Supplementary Fig. 3).
Expression of DEGs is associated
with histological evidence for nerve
regeneration
We did not identify FDR-adjusted significant correlations on
the individual level between the RNA sequencing determined
fold change of the 31 significant DEGs and (i) the fold
change; or (ii) differences in IENFD and mean nodal length
post-surgery versus pre-surgery.
We also defined four phenotypic groups (quarters)
based on the continuous IENFD and nodal length fold
change quartiles and tested for significant associations of
these groups with baseline DEG expression. Whereas no
relationship was detected for nodal length, this analysis
revealed that IENFD fold change quarters were signifi-
cantly dependent on ADCYAP1, DLX1, PRKG2,
ADHFE1, and PIK361 baseline expression (P5 0.05).
ADCYAP1 (Fig. 3D) and ADHFE1 are upregulated in all
IENFD fold change quarters compared to the lowest quar-
ter of patients with negative IENFD fold change, i.e. those
who continue to degenerate. PRKG2 is upregulated and
DLX1 and PIK3R6 are downregulated in patients belong-
ing to the third and fourth quarter.
PACAP is expressed in human skin
and facilitates neurite outgrowth
in vitro
We confirmed the localization of PACAP staining within
the deeper epidermis close to the basement membrane as
well as within sensory afferents in human skin
using immunohistochemistry (Fig. 4A and B and
Table 4 Clinical, quantitative sensory testing and histological outcomes in CTS patients who did not undergo
surgery
Baseline Follow-up P-value
Questionnaires
Mean VAS (SD)
Pain 2.3 (3.0) 1.1 (1.5) 0.268
Numbness 3.8 (3.2) 1.6 (2.2) 0.063
Paraesthesia 3.9 (2.8) 2.6 (3.0) 0.271
Mean Boston scale (SD)
Symptoms 2.3 (0.6) 2.0 (0.6) 0.215
Function 1.9 (0.6) 1.6 (0.5) 0.171
Mean NPSI (SD) 9.7 (7.7) 5.6 (5.8) 0.186
Quantitative sensory testing
CDT, C –3.40 (1.83) –3.23 (1.65) 0.805
WDT, C 4.07 (2.39) 3.96 (1.98) 0.914
TSL, C 6.53 (2.72) 6.90 (3.73) 0.874
MDT, mN 1.27 (1.48) 1.10 (1.16) 0.980
VDT, x/8 7.44 (0.63) 7.28 (1.15) 0.443
CPT, C 15.31 (8.06) 11.38 (8.68) 0.022
HPT, C 41.12 (2.19) 42.54 (3.00) 0.135
MPT, mN 100.5 (66.9) 111.4 (92.7) 0.565
MPS, 0–100 0.95 (0.84) 0.56 (0.59) 0.042
PPT, kPa 325.5 (97.3) 356.4 (109.7) 0.069
WUR, ratio 1.64 (0.66) 2.24 (0.81) 0.033
Histological parameters
IENFD 6.94 (3.09) 5.61 (3.41) 0.021
Meissner corpuscle density 0.47 (0.31) 0.20 (0.24) 0.010
Subepidermal plexus nerve fibre length 137.0 (176.5) 132.6 (110.1) 0.433
PGP + dermal axon bundles 5.74 (4.20) 4.42 (1.98) 0.299
Ratio of PGP + dermal bundles containing MBP 1.45 (0.42) 1.57 (0.60) 0.710
Nodal length, median [IQR] 2.00 [1.01] 2.72 [2.63] 0.023
% Elongated nodes, median [IQR] 0.00 [4.55] 6.66 [22.22] 0.063
Internodal length 82.8 (25.88) 70.24 (16.83) 0.062
G-ratio 0.84 (0.07) 0.89 (0.06) 0.107
Data are presented as mean (SD) unless indicated otherwise.
CDT = cold detection threshold; CPT = cold pain threshold; HPT = heat pain threshold; IENFD = intraepidermal nerve fibre density (per mm epidermis); MDT = mechanical de-
tection threshold; MPS = mechanical pain sensitivity; MPT = mechanical pain threshold; PPT = pressure pain threshold; TSL = thermal sensory limen; VDT = vibration detection
threshold; WDT = warm detection threshold; WUR = wind-up ratio.
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Supplementary Fig. 4 for antibody specificity).
Quantification confirmed an increase in PACAP protein
levels (intensity) after surgery compared to baseline. Of
note, this was the case for both PACAP within an area of
interest over the epidermis and subepidermal plexus
[including the basement membrane: median pre: 10.25
(IQR 5.15); post: 10.76 (5.78), z = 47, P = 0.047]
(Fig. 4C) as well as PACAP specifically within sensory
neurons [pre: 16.35 (21.00), post: 21.32 (19.00), z = 50,
P = 0.022] (Fig. 4D). The PACAP receptors (PAC1,
VPAC1, VPAC2) are also present in human skin, as evi-
denced by mRNA expression as well as weak PAC1 stain-
ing within some skin sensory afferents (Supplementary
Fig. 5).
Additionally, hiPSCd sensory neurons demonstrated
strong mRNA expression of both ADCYAP1, as well as its
high affinity receptor PAC1 (Fig. 4E). The mRNA of the sec-
ondary receptors VPAC1 and VPAC2 are also expressed,
albeit at lower levels. Immunostaining for PAC1 revealed
that this was predominantly located in cell bodies and
growth cones (Fig. 4F), consistent with a role in promoting
axon outgrowth. Application of PACAP to hiPSCd sensory
neurons increased total neurite outgrowth length in a dose
dependent manner compared to vehicle [mean (SD) vehicle:
397.6 lm (90.5); 100 nM PACAP: 667.6 lm (175.1);
10 lM PACAP: 782.0 lm (83.8), F(2,26) = 23.45,
P5 0.0001, NHDF line] (Fig. 4G, H and Supplementary
Fig. 6 for PACAP binding), confirming a proregenerative
role of PACAP in human sensory neurons. We replicated
these findings in another differentiation of the same cell line
as well as another cell line (AD2, Supplementary Fig. 7).
The selective PAC1 agonist maxadilan had a similar regen-
erative effect on hiPSCd sensory neurons as PACAP [mean
(SD) vehicle: 265.2 lm (66.2); 10 lM PACAP: 336.5 lm
(61.3); 1 lM maxadilan: 346.9 lm (73.12), F(2,24) = 3.96,
P = 0.03, AD2 line] (Fig. 4I).
Figure 3 Molecular signature for nerve regeneration in skin. (A) Volcano plot showing the range of transcriptional changes following
carpal tunnel surgery compared to before surgery; x-axis log2 (fold change), y-axis –log10 (P-value). Significant DEGs according to FDR adjusted
P-value are highlighted and labelled. ADCYAP1, i.e. the gene encoding PACAP, was the most upregulated gene. (B) Gene expression changes (log2
fold change) for DEGs. (C) Top 20 biological process gene ontology (GO) terms from GO enrichment analysis with number of DEGs of total
genes marked for each term on the pie chart. (D) ADCYAP1 is upregulated at baseline in all IENFD fold change quarters compared to the lowest
quarter of patients with negative IENFD fold change, who continue to degenerate after surgery. Graph shows mean normalized log2 read counts
at baseline, standard errors and single datapoints.
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Figure 4 PACAP is expressed in human skin and induces neurite outgrowth in hiPSCd sensory neurons.
(A) Immunohistochemical staining in human finger skin demonstrating presence of PACAP (green) within sensory nerve fibres (PGP9.5, arrows)
and in the deeper epidermis (arrowhead). (B) Enlarged images of PACAP and PGP9.5 co-localization within sensory afferents. Quantification of
PACAP staining intensity reveals an increase in intensity post-surgery compared to baseline within (C) an area including epidermal and subepider-
mal plexus and (D) PGP9.5 + sensory neurons. *P5 0.047. (E) Gene expression strength of ADCYAP1, its main receptor PAC1 as well as second-
ary receptors VPAC1 and VPAC2 and the median expression of all genes in hiPSCd sensory neurons. The y-axis shows RNA-seq log2 normalized
gene counts. Box plots show the median and interquartile range with single data-points depicting each experiment (n = 3 cell lines, two differen-
tiations each). (F) Immunohistochemical staining of hiPSCd sensory neurons demonstrating expression of the PACAP receptor (PAC1, green) in
the soma as well as at the growth cones (5 magnified inset). (G and H) PACAP given to dissociated mature (27 ± 3 weeks old) and replated
hiPSCd sensory neurons enhances neurite outgrowth compared to vehicle in a dose-dependent manner (NHDF line). (I) The selective PAC1
agonist maxadilan induces a similar regenerative effect on hiPSCd sensory neurons as PACAP (AD2 line, 27 ± 3 weeks old). Data are presented
as mean, standard error of the mean (SEM) and single data-points, *P5 0.05, **P5 0.01, ***P5 0.0001.
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Discussion
Little is known about the molecular and cellular determi-
nants of nerve regeneration in humans. Using CTS as a
model system, we demonstrate recovery of large and small
fibre function following surgical nerve decompression; how-
ever, this recovery remains incomplete even 6 months after
surgery. There was significant individual variation in the de-
gree of cutaneous reinnervation, and at group level this did
not reach the level seen in unaffected control individuals.
We identified a significant correlation between both cutane-
ous reinnervation by small fibres and the nodal length of
myelinated sensory fibres, with symptom and functional re-
covery following carpal tunnel decompression, respectively.
Gene expression analysis identified 31 DEGs, with
ADCYAP1 encoding PACAP being most strongly upregu-
lated. Intriguingly, ADCYAP1 expression was associated
with a histological regenerative phenotype and a regenera-
tive role of PACAP and the PAC1 agonist maxadilan was
confirmed in hiPSCd sensory neurons.
Carpal tunnel surgery greatly improved symptoms in the
majority of patients (83%), which is in line with previous
reports of excellent results in 75% of patients (Bland,
2007). The subjective improvement was accompanied by a
significant improvement in somatosensory function for all de-
tection thresholds except warm detection. A selectively
impaired postoperative recovery of warm detection has previ-
ously been reported in patients with entrapment neuropathies
including CTS (Nygaard et al., 1996) and lumbar radiculop-
athy (Tschugg et al., 2016). While this may be attributed to
more subtle deficits in warm than cold detection in CTS
(Westerman and Delaney, 1991), it may also be explained by
a previously observed delayed functional recovery of unmye-
linated C-fibres (encoding warm sensations) compared to A-
fibres (Lang et al., 1995; Gorodetskaya et al., 2009).
At 6 months after surgery, there was a significant reinner-
vation of the skin by epidermal nerve fibres; however, this
remained incomplete. Given the relatively short reinnerva-
tion distance and the previously reported rate of axon regen-
eration (Fugleholm et al., 1994), one may have expected a
higher rate of reinnervation. However, this slow regener-
ation of small epidermal fibres is in line with previous pre-
clinical work (McLachlan et al., 1994; Lindenlaub and
Sommer, 2002) and experimental human studies (Polydefkis
et al., 2004; Petersen and Rowbotham, 2010). It has been
suggested that the epidermal layer of the skin may be a rela-
tively hostile environment for regenerating fibres as demon-
strated by incomplete epidermal regeneration while dermal
reinnervation is successful (Navarro et al., 1997; Rajan
et al., 2003). Here, we could not find a postoperative in-
crease in the subepidermal plexus length or number of der-
mal axon bundles. The available quantification methods
may, however, not be sensitive to detect relatively subtle
changes in dermal small fibres amidst the abundance of large
fibres. Alternatively, dermal reinnervation may indeed re-
main incomplete or only reach subdermal levels, as previous-
ly shown for SP + axons (small peptidergic fibres) following
experimental nerve injury (McLachlan et al., 1994). The
slow rate of reinnervation emphasizes the point that any fu-
ture trials of agents to promote nerve regeneration in which
epidermal nerve fibres are used as an outcome measure
would need to be of significant duration.
Meissner corpuscle and dermal myelinated bundle density
in CTS patients were comparable to controls at baseline and
remained unaltered after surgery despite a clear improve-
ment in large fibre function assessed by QST (mechanical
and vibration detection thresholds). Presumably, the large
fibre dysfunction in CTS is driven by ischaemic and demyeli-
nating changes at the lesion site—as has been shown in ex-
perimental (Schmid et al., 2013) and clinical nerve
compression (Mackinnon et al., 1986)—rather than axon
degeneration and changes to target tissue receptors (Schmid
et al., 2013, 2014). This is supported by the significant, al-
beit incomplete recovery of electrophysiological properties
over the affected wrist segment following surgical decom-
pression. Persistence of thin myelin sheets after remyelination
(Gupta and Steward, 2003; Duncan et al., 2017) may ac-
count for the continuing conduction slowing.
Unlike in a previous cohort (Schmid et al., 2014), patients
with CTS did not have an increased nodal length at baseline.
Since the presence of elongated nodes seems to be protective
in nature (Schmid et al., 2014), this disparity may be caused
by the inclusion of patients with more severe symptoms in
this surgical cohort (not showing protective nodal elong-
ation) compared to the patients with milder symptomatology
in the previous cohort (Schmid et al., 2014). Of note, nodal
length significantly increased following surgery, further cor-
roborating a protective effect. The mechanism underlying
the presence of elongated nodes remains speculative, but it
could be associated with the dynamic process of demyelin-
ation or remyelination (Suzuki et al., 1969). Indeed,
increased nodal length can be found in patients with demye-
linating neuropathies (Doppler et al., 2013). Given the asso-
ciation with decreased symptoms in our first cohort and the
increased presence of elongated nodes after surgery and their
correlation with functional recovery in the present cohort,
an association with remyelination in patients with CTS
seems more likely. Alternatively, it has been demonstrated
that the incorporation of cytoskeletal and ion channel com-
ponents to nodes of Ranvier requires vesicular transport
(Zhang et al., 2012). It is therefore possible that the restor-
ation of axon transport following carpal tunnel surgery
enhances delivery of nodal components and nodal lengthen-
ing. Elongated nodes may also reflect nerve fibre lengthening
during nerve regeneration, as has been shown in experimen-
tal limb lengthening in the rabbit (Kerns et al., 2001). The
axon and its associated Schwann cell are closely linked at
the septate-like junction of the paranode. Lengthening may
therefore be more easily achieved at the node rather than at
the internode, which would require increased length of both
axon and Schwann cell.
We identified a large degree of interindividual variation in
the extent of small fibre regeneration and nodal changes,
which correlate with clinical recovery. Currently, therapeutic
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targets that promote nerve regeneration in humans are lack-
ing. Using CTS as a model system, we hypothesized that we
could identify a transcriptional signature in the skin that
would show a relationship to successful reinnervation by
sensory axons. We identified ADCYAP1 as the most upregu-
lated gene (3.7-fold change) using RNA-seq. We confirmed
this upregulation at mRNA level with droplet digital PCR
and at protein level with immunostaining. The increased
mRNA expression was associated with histological evidence
of neural regeneration. ADCYAP1 encodes PACAP, which
is a pleiotropic secreted molecule that has been associated
with cell survival in neurodegenerative conditions
(Bonaventura et al., 2018) as well as growth cone guidance
(Lioudyno et al., 1998) and increased neurite outgrowth of
peripheral afferent neurons in preclinical models (Lioudyno
et al., 1998; Suarez et al., 2006; Fukiage et al., 2007;
Nakajima et al., 2013).
Immunohistochemical studies in cadavers have shown that
PACAP is expressed in trigeminal ganglia neurons
(Frederiksen et al., 2018) as well as small-to-intermediate
sized DRG neurons and the superficial dorsal horn of the
spinal cord (Dun et al., 1996), consistent with expression in
sensory afferents. Equally, animal studies have shown that
PACAP is expressed in small-to-medium sized DRG neurons
(Moller et al., 1993) and upregulated during the regenerative
process following nerve injury (Zhang et al., 1995, 1996;
Woodley et al., 2019), including nerve compression
(Pettersson et al., 2004). In relation to localization, we could
identify PACAP in sensory afferents and the deeper epider-
mis in human skin. Whereas future studies are required to
determine the source of this PACAP, it may be expressed by
keratinocytes (Fig. 4), released and subsequently bound to its
receptor PAC1 (which we found was expressed on sensory
skin afferents as well as the growth cones of hiPSCd sensory
neurons). Indeed, human keratinocytes have previously been
shown to express low levels of ADCYAP1 mRNA (Granoth
et al., 2000) and may therefore have a paracrine function.
Alternatively, we also found that ADCYAP1 mRNA is
expressed by hiPSCd sensory neurons and therefore may
have an autocrine action on these neurons, as previously
reported in injured vagus nerves (Reimer et al., 1999).
Whereas a regenerative function of PACAP on sensory
neurons has been demonstrated for central (Guirland et al.,
2003; Ogata et al., 2015) and peripheral neurons (Suarez
et al., 2006; Wu et al., 2006; Nakajima et al., 2013) in ani-
mals, its effects on neurite outgrowth in human neurons has
not previously been tested. One study reported that PACAP
can rescue hiPSCd motor neurons from apoptosis
(Bonaventura et al., 2018). We found that administration of
PACAP to mature hiPSCd sensory neurons resulted in a
dose-dependent increase in neurite outgrowth in vitro, thus
confirming a direct regenerative action of PACAP on human
sensory neurons. PACAP has also been shown to facilitate
nerve regeneration through its action on Schwann cells and
regulation of the inflammatory response by macrophages
(Woodley et al., 2019). These mechanisms may further
contribute to the regenerative phenotype associated with
PACAP in vivo. Intriguingly, the selective PAC1 agonist max-
adilan had a similar regenerative effect on hiPSCd sensory
neurons, suggesting that manipulation of PACAP/PAC1 may
have therapeutic potential in human sensory nerve
regeneration.
Whereas we concentrated on ADACYAP1 as it was the
most strongly DEG, its expression correlated with cutaneous
reinnervation and had a plausible biological function, several
of the other DEGs have been implicated with neurogenesis
or neuronal survival. For instance, SP8 and SP9 regulate
interneuron development in the olfactory bulb (Li et al.,
2018), ZIC1 has been implicated with neural development
(Aruga, 2004), DLX1 is necessary for survival of developing
retinal ganglion cells (de Melo et al., 2005) and periostin
expressed by POSTN plays an essential role in axon regen-
eration following spinal cord injury (Shih et al., 2014).
DNAJB4 is another interesting candidate as it is axonally
transcribed (Gomes et al., 2014). Of note, a number of
DEGs were also significantly associated with cutaneous rein-
nervation in patients (e.g. DLX1, PRKG2, ADHFE1,
LINC01835, PIK361). Our dataset can therefore be further
exploited to identify biomarkers of and therapeutic targets
relating to neural regeneration in humans.
Our unbiased RNA sequencing approach did not identify
neurotrophins, which are implicated with skin innervation in
preclinical models (Truzzi et al., 2011). Closer inspection of
the expression levels of the neurotrophin family in our ex-
periment confirmed that levels were unchanged when com-
paring before and after surgery (Supplementary Fig. 8), thus
excluding a potential concealment of changes due to strin-
gent corrections for multiple testing. The absence of differen-
tial expression of neurotrophins in our study may be
attributed to several factors. First, the heterogeneity of cells
within the skin may dilute potential changes in neurotrophin
expression within specific cell types (e.g. keratinocytes versus
fibroblasts or immune cells). Second, the molecular signature
involved in regeneration following chronic partial denerv-
ation (such as in CTS) may not be comparable with the re-
generative response modelled in preclinical studies, which
mostly use acute denervations. The clinical literature related
to neurotrophin levels in the skin of patients with neuropa-
thies is controversial. Whereas some studies report a de-
crease in neutrophin levels (Anand et al., 1996; Uceyler
et al., 2015), others found increased levels (Kennedy et al.,
1998; Diemel et al., 1999) compared to healthy controls. Of
note, a recent study reported higher levels of neurotrophin
family mRNA in patients with diabetic neuropathy follow-
ing pancreas/kidney transplantation compared to diabetic
patients and healthy controls (Saudek et al., 2018). In ac-
cordance with our findings however, serial skin evaluation
before and after glucose homeostasis did not reveal changes
in neurotrophin expression profiles. Also, neurotrophin ex-
pression was not related to regeneration of peripheral sen-
sory fibres. Importantly, our work focused on gene
expression and we can therefore not make inferences about
protein levels. Future work is required to further elucidate a
potential role of neurotrophins in human nerve regeneration.
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Limitations of the study and future
directions
Because of the ethical consideration of not withholding treat-
ment, and given that our primary aim was to determine
nerve regeneration and its relationship to functional recov-
ery, our study used a prospective cohort rather than a trial
design of randomizing patients to surgical intervention or
conservative management. Nevertheless, we continued to fol-
low-up 13 patients who decided not to undergo surgery.
The small sample and the absence of randomization with
lower age and symptom severity in non-operated patients
precludes a direct comparison. However, the progressive
structural decline of small nerve fibres identified in this
group is intriguing, and the potential implications for man-
agement of these patients warrants further investigation.
We have performed the RNA-seq experiment in skin sec-
tions containing a range of cellular components of both
neural and non-neural origin. The exact tissue types contri-
buting to the differential expression of ADCYAP1 therefore
remains unknown. Whereas future work is required to deter-
mine the potential source of PACAP, our experiments sug-
gest that it can promote axon outgrowth in a human
sensory neuronal model.
While we have shown that PACAP is significantly upregu-
lated following cutaneous reinnervation and can promote
axon outgrowth in a human sensory neuronal model, deter-
mining the exact downstream signalling pathway of PACAP/
PAC1-induced neurite outgrowth was beyond the scope of
this manuscript, but would be an interesting avenue for fu-
ture research. Previous experimental work suggests that
PACAP induced neurite outgrowth is cAMP-dependent
(Guirland et al., 2003; Ravni et al., 2008; Emery and Eiden,
2012) with at least two distinct pathways involved, one of
which is PKA-dependent/ERK-independent and the other
PKA-independent/ERK-dependent (Emery and Eiden, 2012).
Given the multimodal actions of cAMP, targeting upstream
at PACAP/PAC1 as a treatment to promote neural regener-
ation in vivo may be more promising. Exploitation of
PACAP will however require consideration of optimal deliv-
ery given that systemic treatment can trigger migraine (Guo
et al., 2016). In fact, function blocking antibodies to PAC1
are undergoing clinical testing for migraine treatment
(Amgen) and given our findings, care will need to be taken
that such treatments do not impair sensory neuron function
in the context of co-existing neuropathy. One means of opti-
mizing delivery to promote neurite outgrowth of small fibres
would be to develop small molecule agonists of PAC1 that
can be given locally, as has been achieved for PAC1 antago-
nists (Takasaki et al., 2018) and other growth promoting
molecules, such as GDNF (Sidorova et al., 2017).
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